What 4 Analyst Ratings Have To Say About United Therapeutics
Portfolio Pulse from Benzinga Insights
United Therapeutics (NASDAQ:UTHR) has received four analyst ratings in the last quarter, all of which were either bullish or somewhat bullish. The average 12-month price target for the company, according to these analysts, is $298.25, a figure that has increased by 2.03% over the past month.
August 04, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially lead to a short-term increase in its stock price.
Analyst ratings often influence investor sentiment. In this case, United Therapeutics has received all bullish ratings, which indicates a positive outlook for the company's stock. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100